Cantor Fitzgerald Estimates Organogenesis FY2026 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Organogenesis in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn $0.16 per share for the year. The consensus estimate for Organogenesis' current full-year earnings is ($0.07) per share.

Separately, Morgan Stanley increased their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Down 3.2%

ORGO stock traded down $0.10 during trading on Wednesday, reaching $3.07. The stock had a trading volume of 494,799 shares, compared to its average volume of 1,161,634. Organogenesis has a one year low of $2.28 and a one year high of $6.71. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company's 50 day moving average is $3.75 and its two-hundred day moving average is $3.83. The company has a market capitalization of $389.44 million, a price-to-earnings ratio of -51.17 and a beta of 1.63.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million.

Insider Activity

In related news, insider Lori Freedman bought 9,022 shares of Organogenesis stock in a transaction dated Friday, June 6th. The stock was purchased at an average cost of $2.99 per share, with a total value of $26,975.78. Following the transaction, the insider now directly owns 846,459 shares of the company's stock, valued at approximately $2,530,912.41. The trade was a 1.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 252,264 shares of company stock valued at $725,732 in the last three months. Company insiders own 33.00% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ORGO. SG Americas Securities LLC boosted its holdings in Organogenesis by 66.4% in the 4th quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock worth $134,000 after buying an additional 16,660 shares during the period. Rhumbline Advisers boosted its holdings in Organogenesis by 7.1% in the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock worth $369,000 after buying an additional 7,621 shares during the period. Palumbo Wealth Management LLC bought a new position in Organogenesis in the 4th quarter worth approximately $65,000. Bank of New York Mellon Corp boosted its holdings in Organogenesis by 35.5% in the 4th quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company's stock worth $1,340,000 after buying an additional 109,762 shares during the period. Finally, Cornerstone Investment Partners LLC bought a new position in Organogenesis in the 4th quarter worth approximately $162,000. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.